2019³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦17Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2019-05-17±³À°ÀÏÀÚ : 2019-05-17
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ(¼Ò°øµ¿), Crystal Ballroom (2F)
±³À°ÁÖÁ¦ :
2019³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦17Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo3@ksmo.or.kr ±³À°Á¾·ù : ³»°ú, »êºÎÀΰú, ÀçÈ°ÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú¾à¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï- ȸ¿ø : 40,000, ÁØȸ¿ø : 30,000, 65¼¼ ÀÌ»ó : ¹«·á -ºñȸ¿ø ±³¼ö, Àü¹®ÀÇ ¹Ú»ç±Þ ¿¬±¸¿ø : 50,000ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 40,000ÇöÀåµî·Ï- ȸ¿ø : 60,000, ÁØȸ¿ø :50,000, 65¼¼ ÀÌ»ó : ¹«·á - ºñȸ¿ø±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø : 70,000ÀüÀÓÀÇ,Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 60,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 09:00~09:25 Cancer genomics and NGS (variants Á¾·ù, NGS ¿ø¸®, platform Á¾·ù, ºÐ¼®°úÁ¤, µ¥ÀÌÅÍ format) ±èÁö¿ø(ºÐ´ç¼¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 09:25~09:50 Knowledge base for interpretation of NGS (NGS Çؼ® °úÁ¤, Âü°íÇÏ´Â knowledge base Á¾·ù ¹× Ư¼º) ±èÅÂÁ¤(¿©Àǵµ¼º¸ðº´¿ø º´¸®°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 09:50~10:00 Molecular tumor board with in-house NGS panel (experiences centers with in-house panel and BI) ¿ÁÂù¿µ(¼¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 10:00~10:10 Molecular tumor board with outsourced NGS panel (experiences centers without in-house panel and BI) ÀÌÀ±±Ô(°ºÏ»ï¼ºº´¿ø Á¾¾çÇ÷¾×³»°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 10:10~10:20 Current trends and issues in molecular tumor board À±½Å±³(¼¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú)
Åä·Ð 05-17 Crystal Ballroom A (2F) 10:20~10:40 Panel Discussion ()
ÈÞ½Ä 05-17 Crystal Ballroom A (2F) 10:40~11:00 Coffee Break ()
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 11:00~11:45 Chromosomal instability and genome plasticity in cancer evolution, immune evasion and metastasis Robert Charles SWANTON(Francis Crick Institute)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 11:45~12:30 Evolution of Immunotherapies in the treatment of non-small cell lung cancer Edward Garon(UCLA)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 12:30~13:10 The new standard of care in stage III unresectable NSCLC‐one step forward to cure ¼±Á¾¹«(¼º±Õ°üÀÇ´ë Ç÷¾×Á¾¾ç³»°ú)
±âŸ 05-17 Crystal Ballroom A (2F) 13:10~13:30 Á¤±âÃÑȸ ¿Àµµ¿¬(KSMO Ãѹ«ÀÌ»ç)
±âŸ 05-17 Crystal Ballroom A (2F) 13:30~13:50 Awards ±èÅÂÀ¯(KSMO ÀÌ»çÀå)
ÈÞ½Ä 05-17 Crystal Ballroom A (2F) 13:50~14:10 Coffee Break ()
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 14:10~14:30 Validation for assessment tool, sheffiled profile for assessment and referral to care (SPARC), to identify supportive and palliative care needs in cancer patients ±ÇÁ¤Çý(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 14:30~14:50 The effect of Fusobacterium nucleatum infection on chemoresistance in patients with inoperable metastatic colorectal ±èÇÑ»ó(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 14:50~15:10 Immunotherapy in GC/esophageal cancer ¹Ú¼÷·Ã(¿ï»êÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 15:10~15:30 Emerging molecular targets in biliary cancer ÃÖÇýÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 15:30~15:50 Recent progress in treatment of hepatocellular carcinoma À̸í¾Æ(°¡Å縯ÀÇ´ë)
Åä·Ð 05-17 Crystal Ballroom A (2F) 15:50~16:00 Discussion ()
ÈÞ½Ä 05-17 Crystal Ballroom A (2F) 16:00~16:20 Coffee Break ()
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 16:20~16:40 Mode of action and development ÀÓ¼®¾Æ(¼¿ïÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 16:40~17:00 Clinical application in breast cancer À̼öÀÌ(µ¿¾ÆÀÇ´ë Ç÷¾×Á¾¾ç³»°ú)
±³À°½Ã°£ 05-17 Crystal Ballroom A (2F) 17:00~17:20 Clinical application in ovarian cancer ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë »êºÎÀΰú)
Åä·Ð 05-17 Crystal Ballroom A (2F) 17:20~17:30 Discussion ()